Umbilical Cord Stem Cells: Legitimate Use vs Clinic Products

Umbilical cord products split into two categories that clinics routinely blur together. The first is cord-blood-derived hematopoietic stem cells, which are the only stem cell product FDA-approved for use in the United States, and only for one purpose: restoring blood and immune function in patients with hematopoietic-system disorders, given by licensed transplant centers under strict collection and testing rules [1][2]. The second is everything else sold under an umbilical-cord label at outpatient clinics and medspas: umbilical cord tissue products, Wharton's jelly extracts, and cord-blood or cord-tissue products marketed for orthopedic pain, anti-aging, or general wellness. None of that second category has FDA approval, and none of it does what the cord-blood transplant does [2][3].

The clearest evidence of what goes wrong sits in a 2018 multistate outbreak. On September 12, 2018, three Texas patients received injections of an unapproved umbilical-cord-blood-derived product processed by Genetech, Inc. and distributed by Liveyon, LLC; five days later the Texas Department of State Health Services was notified of bloodstream infections in all three [4]. Separately, four Florida patients injected with the same product line between February 15 and August 30, 2018 developed joint infections, reported to the Florida Department of Health on September 22, 2018 [4]. By December 14, 2018 the CDC had logged 12 confirmed patients across three states (seven in Texas, four in Florida, one in Arizona), all hospitalized, none died [4][5]. Identified organisms included Enterobacter cloacae, Citrobacter freundii, E. coli, Enterococcus faecalis, and Proteus mirabilis, and lab testing found unopened, unused vials of the product itself were contaminated [4][5]. A later, fuller investigation reported in MedPage Today put the real toll higher: 20 patients with infections including bloodstream infections, joint infections, and epidural abscesses, 19 of them hospitalized, after 34 sampled unopened Liveyon vials showed a 65% contamination rate across 16 different bacterial species [6]. FDA Commissioner Scott Gottlieb said at the time that "the company's failure to put in place appropriate safeguards may have led to serious blood infections in patients" [4]. Liveyon recalled the product and stopped distribution; its former CEO, John Kosolcharoen, who created both Genetech and Liveyon in 2016, was later convicted over the scheme [6].

This was not an isolated incident. California's health department separately flagged infections tied to a different product, the ReGen Series, also Genetech-manufactured and Liveyon-distributed, plus other non-FDA-approved umbilical cord blood products causing bloodstream, joint, and spinal infections, tumor formation at injection sites, and one case of blindness after eye injection [7]. And the enforcement pattern has not stopped: on February 11, 2026 the FDA sent a warning letter to Dynamic Stem Cell Therapy in Henderson, Nevada, over an umbilical-cord-derived allogeneic product marketed for sports injuries (knee, shoulder, ankle, hip) and separately marketed as "anti-aging stem cell therapy," both classified as an unapproved drug and biological product under section 351 of the Public Health Service Act [8]. A December 30, 2024 warning letter to Evolutionary Biologics, Inc. cited two more umbilical-cord products, EVO JEL and EVO HYBRID, plus a Wharton's jelly-exosome product, all lacking a Biologics License Application [9].

The regulatory logic behind all of this is simple and stated by the FDA directly: a product recovered from another person's body, marketed for a use unrelated to the donor's own hematopoietic system, and not intended for "homologous use only," does not qualify for the light-touch tissue-donation pathway and instead needs the same premarket drug and biologics review as any injectable medicine [1][3][9]. Registration on ClinicalTrials.gov or a company's own FDA facility listing does not mean a product is legally marketed; the FDA states this explicitly because clinics routinely cite trial registration as if it were approval [3].

Practical read for anyone offered an umbilical cord product outside a hematology transplant setting: ask whether an active investigational new drug application covers the specific product, ask for the manufacturer name and lot number, and check that name against the FDA's public warning letter database before paying. Cord-blood hematopoietic transplants for blood disorders are legitimate, decades-proven medicine [1][2]. Umbilical cord products sold for pain, joints, or anti-aging outside that narrow approved use carry a documented infection track record and an active, ongoing FDA enforcement history running through 2026 [4][5][6][8][9].